Cancer Mutation Detection with Digital PCR - Summary - MDSpire
Feature

Cancer Mutation Detection with Digital PCR

Evaluating rapid assays for the detection of somatic mutations in tissue and liquid biopsies

  • April 15, 2026

  • 9 min

Share

Digital PCR (dPCR) has revolutionized oncological diagnostics, offering rapid screening for mutations and minimal residual disease monitoring. In a presentation by Dr. Valentina De Pascale from IRCCS Regina Elena National Cancer Institute, validation studies for dPCR assays targeting TERT and KRAS mutations were discussed, showcasing 100% concordance with reference methods in patient samples. dPCR's capabilities in detecting mutations in difficult samples make it a promising tool for precision oncology, potentially transforming routine diagnostic workflows in the future.

Original Source(s)

Cancer Mutation Detection with Digital PCR

  • April 15, 2026

Related Content

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

Trends and Challenges in Nitrosamine Testing Part Four The Regulatory Landscape

Following part two, which explored the analytical challenges involved in nitrosamine testing, our experts return to offer their top tips for building a method from scratch

  • April 17, 2026

  • 6 min
Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...